A Novel Multicolor Flow Cytometry Scoring System for the Diagnosis and Prognostic Stratification of Myelodysplastic Syndromes

Clin Lab. 2022 Sep 1;68(9). doi: 10.7754/Clin.Lab.2021.201116.

Abstract

Background: Myelodysplastic syndromes (MDS) are a class of myeloid neoplasms featuring inefficient maturation and differentiation of hematopoietic cells, blood cytopenia, and a high risk of leukemia onset. The diagnosis of MDS remains a challenging task owing to its complexity, heterogeneity, and the lack of specific characteristics.

Methods: To look for an easy and inexpensive diagnostic method for MDS, we tried to establish an FCM scoring systems (FCSS) with a combination of antibodies for diagnosis and prognostic stratification of MDS. This FCSS adopted four parameters; i.e., the frequency of myeloblasts in nucleated cells, the ratio between pro-B cells and CD117+ cells, the ratio of CD45 mean fluorescence intensity between lymphocytes and myeloblasts, and the ratio of SSC peak values between mature granulocytes and lymphocytes.

Results: We tested the correlation between the total FCSS score with conventional IPSS-R. Additionally, the correlation between the score of each FCSS parameter and IPSS-R was also evaluated. We found that total FCSS score had a positive correlation with IPSS-R, while FCSS parameter 1 and 4 were also correlated with IPSS-R. Furthermore, this FCSS had a sound sensitivity and specificity in the diagnosis of MDS.

Conclusions: The FCSS represents a convenient and affordable approach for the diagnosis and prognostic stratification of MDS.

MeSH terms

  • Ferric Compounds
  • Flow Cytometry / methods
  • Humans
  • Leukemia*
  • Leukocyte Count
  • Maltose / analogs & derivatives
  • Myelodysplastic Syndromes* / diagnosis
  • Prognosis

Substances

  • Ferric Compounds
  • ferric carboxymaltose
  • Maltose